scholarly journals Associations Between CD160 Polymorphisms and Autoimmune Thyroid Disease: A Case-Control Study

2020 ◽  
Author(s):  
Weiwei He ◽  
Jing Zhao ◽  
Xuerong Liu ◽  
Sheli Li ◽  
Kaida Mu ◽  
...  
Keyword(s):  
Logistic Regression ◽  
Thyroid Disease ◽  
Autoimmune Thyroid Disease ◽  
Additive Model ◽  
Graves Disease ◽  
Dominant Model ◽  
Regression Analyses ◽  
Age And Gender ◽  
Autoimmune Thyroid ◽  
And Gender

Abstract Background/AimsRecent researches suggest that the CD160/HVEM/LIGHT/BTLA signaling pathway may contribute to the pathogeneses of autoimmune diseases, but the relationship between CD160 polymorphisms and autoimmune thyroid disease (AITD) has not been reported yet. This study aimed to evaluate the associations between CD160 polymorphisms and AITD.MethodsA total of 1017 patients with AITD (634 Graves' disease and 383 Hashimoto's thyroiditis) and 856 unrelated healthy controls were recruited into our study. Odds ratios (ORs) with 95% confidence interval (95%CI) were calculated through logistic regression analyses. The CD160 SNPs were detected using Hi-SNP high-throughput genotyping. ResultsThere was a statistically significant difference between Graves' disease patients and the control group with respect to both the genotype distribution (P=0.014) and allele frequency of rs744877 (P=0.034). A significant association of CD160 rs744877 with AITD was observed before adjusted age and gender under a dominant model (OR= 0.79, 95%CI 0.66-0.95; P= 0.013) and an additive model (OR= 0.77, 95%CI 0.64-0.94, P=0.008), and was also observed after adjusted age and gender under a dominant model (OR= 0.78, 95%CI 0.65-0.95; P= 0.011) and an additive model (OR= 0.76, 95%CI 0.63-0.93, P=0.007). A significant association of rs744877 with Graves' disease was observed under an allele model (OR= 0.84, 95%CI 0.71-0.98, P=0.027), a dominant model (OR= 0.74, 95%CI 0.60-0.91; P= 0.005), and an additive model (OR= 0.72, 95%CI 0.58-0.90, P=0.004). Multivariate logistic regression analyses suggested that the association remained significant after adjustment for age and gender. However, rs744877 was not related to Hashimoto's thyroiditis. Furthermore, CD160 rs3766526 was not significantly related to either Graves' disease or Hashimoto's thyroiditis.ConclusionThis is the first identification of the association of CD160 rs744877 with Graves' disease. Our findings add new data to the genetic contribution to Graves' disease susceptibility and support the crucial role of the CD160/HVEM/LIGHT/BTLA pathway in the pathogenesis of Graves' disease.

scholarly journals Associations between CD160 polymorphisms and autoimmune thyroid disease: a case-control study

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Weiwei He ◽  
Jing Zhao ◽  
Xuerong Liu ◽  
Sheli Li ◽  
Kaida Mu ◽  
...  
Keyword(s):  
Hashimoto’S Thyroiditis ◽  
Autoimmune Thyroid Disease ◽  
Additive Model ◽  
Hashimoto's Thyroiditis ◽  
Graves Disease ◽  
Dominant Model ◽  
Regression Analyses ◽  
Age And Gender ◽  
Autoimmune Thyroid ◽  
And Gender

Abstract Background Recent researches suggest that the CD160/HVEM/LIGHT/BTLA signaling pathway may contribute to the pathogeneses of autoimmune diseases, but the relationship between CD160 polymorphisms and autoimmune thyroid disease (AITD) has not been reported yet. This study aimed to evaluate the associations between CD160 polymorphisms and AITD. Methods A total of 1017 patients with AITD (634 Graves’ disease and 383 Hashimoto’s thyroiditis) and 856 unrelated healthy controls were recruited into our study. Odds ratios (ORs) with 95% confidence interval (95%CI) were calculated through logistic regression analyses. The CD160 SNPs were detected using Hi-SNP high-throughput genotyping. Results There was a statistically significant difference between Graves’ disease patients and the control group with respect to both the genotype distribution (P = 0.014) and allele frequency of rs744877 (P = 0.034). A significant association of CD160 rs744877 with AITD was observed before adjusted age and gender under a dominant model (OR = 0.79, 95%CI 0.66–0.95; P = 0.013) and an additive model (OR = 0.77, 95%CI 0.64–0.94, P = 0.008), and was also observed after adjusted age and gender under a dominant model (OR = 0.78, 95%CI 0.65–0.95; P = 0.011) and an additive model (OR = 0.76, 95%CI 0.63–0.93, P = 0.007). A significant association of rs744877 with Graves’ disease was observed under an allele model (OR = 0.84, 95%CI 0.71–0.98, P = 0.027), a dominant model (OR = 0.74, 95%CI 0.60–0.91; P = 0.005), and an additive model (OR = 0.72, 95%CI 0.58–0.90, P = 0.004). Multivariate logistic regression analyses suggested that the association remained significant after adjustment for age and gender. However, rs744877 was not related to Hashimoto’s thyroiditis. Furthermore, CD160 rs3766526 was not significantly related to either Graves’ disease or Hashimoto’s thyroiditis. Conclusion This is the first identification of the association of CD160 rs744877 with Graves’ disease. Our findings add new data to the genetic contribution to Graves’ disease susceptibility and support the crucial role of the CD160/HVEM/LIGHT/BTLA pathway in the pathogenesis of Graves’ disease.

Development of Autoimmune Thyroid Disease in Multiple Sclerosis Patients Post-Alemtuzumab Improves Treatment Response

2020 ◽  
Vol 105 (9) ◽  
pp. e3392-e3399 ◽  
Author(s):  
Alina Sovetkina ◽  
Rans Nadir ◽  
Antonio Scalfari ◽  
Francesca Tona ◽  
Kevin Murphy ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Thyroid Disease ◽  
Autoimmune Thyroid Disease ◽  
Graves Disease ◽  
Autoimmune Thyroid ◽  
Tertiary Referral Center ◽  
T2 Lesions ◽  
Relapsing Remitting ◽  
Edss Score ◽  
Multiple Sclerosis Patients

Abstract Context Alemtuzumab is an anti-CD52 monoclonal antibody used in the treatment of relapsing-remitting multiple sclerosis (MS). Between 20% and 40% of alemtuzumab-treated MS patients develop autoimmune thyroid disease (AITD) as a side effect. Objective The objective of this work is to determine whether MS disease progression following alemtuzumab treatment differs in patients who develop AITD compared to those who do not. Design, Setting, and Patients A retrospective analysis of 126 patients with relapsing-remitting MS receiving alemtuzumab from 2012 to 2017 was conducted at a tertiary referral center. Main Outcome Measures Thyroid status, new relapses, Expanded Disability Status Scale (EDSS) score change, and disability progression following alemtuzumab were evaluated. Results Twenty-six percent (33 out of 126, 25 female, 8 male) of alemtuzumab-treated patients developed AITD, 55% of which was Graves disease. EDSS score following alemtuzumab was reduced in patients who developed AITD compared to those who did not (median [interquartile range]; AITD: –0.25 [–1 to 0.5] vs non-AITD: 0 [1-0]. P = .007]. Multivariable regression analysis confirmed that the development of AITD was independently associated with EDSS score improvement (P = .011). Moreover, AITD patients had higher relapse-free survival following alemtuzumab (P = .023). There was no difference in the number of new focal T2 lesions and contrast-enhancing magnetic resonance imaging lesions developed following alemtuzumab between the 2 groups. Conclusion Graves disease was the most common form of AITD developed by MS patients following alemtuzumab. This study suggests that MS patients who develop AITD may have an improved response to alemtuzumab, as measured by reduced disability and lower relapse rate.

scholarly journals A Case of Thyrotoxicosis due to Simultaneous Occurrence of Subacute Thyroiditis and Graves’ Disease

2018 ◽  
Vol 2018 ◽  
pp. 1-3
Author(s):  
Kazunori Kageyama ◽  
Noriko Kinoshita ◽  
Makoto Daimon
Keyword(s):  
Thyroid Hormones ◽  
Thyroid Disease ◽  
Rare Case ◽  
Autoimmune Thyroid Disease ◽  
Subacute Thyroiditis ◽  
Simultaneous Occurrence ◽  
Graves Disease ◽  
Inflammatory Disorder ◽  
Autoimmune Thyroid ◽  
Prompt Diagnosis

Subacute thyroiditis is an inflammatory disorder of the thyroid. Graves’ disease is an autoimmune thyroid disease in which thyroid hormones are overproduced. Here we present a rare case of thyrotoxicosis due to the simultaneous occurrence of both diseases. Prompt diagnosis and therapy are required to prevent complications in patients with thyrotoxicosis.

Exploring Prospective Predictors of Completed Suicides

Crisis ◽  
2014 ◽  
Vol 35 (4) ◽  
pp. 233-244 ◽  
Author(s):  
William Feigelman ◽  
Zohn Rosen ◽  
Bernard S. Gorman
Keyword(s):  
Logistic Regression ◽  
Suicide Risk ◽  
Assessment Tool ◽  
Regression Analyses ◽  
Chi Square ◽  
Age And Gender ◽  
Social Surveys ◽  
Completed Suicide ◽  
Life Circumstances ◽  
And Gender

Background: This study was based on over 30,000 respondents who completed General Social Surveys between 1978 and 2002. Aims: We approached these respondents prospectively, comparing and contrasting the responses of those who subsequently died by suicide (N = 141) with those who died from all other causes (N = 9,115). Method: We employed chi-square and logistic regression analyses of important demographic confounders to test for statistically significant differences between suicide decedents and all other decedents. Results: Suicide decedents died on average 2 years sooner than all other decedents. When covariates of age and gender were applied, suicide decedents exhibited greater acceptance of suicide for dealing with various adverse life circumstances, were more likely to have been the gun owners in their households, lived in regions where gun ownership was more commonplace, and held less strong religious beliefs and less of a belief of an afterlife. Conclusion: The observed affinity between attitudes of suicide acceptability and completed suicide suggests a potential for creating a meaningful assessment tool to identify those positioned at the extreme end of the suicide risk continuum.

scholarly journals Autoimmune Thyroid Disease and Psoriasis Vulgaris after COVID-19 in a Male Teenager

2021 ◽  
Vol 2021 ◽  
pp. 1-3
Author(s):  
Nadia K. Qureshi ◽  
Sanjay K. Bansal
Keyword(s):  
Family History ◽  
Thyroid Disease ◽  
Autoimmune Thyroid Disease ◽  
Psoriasis Vulgaris ◽  
Thyroid Diseases ◽  
Graves Disease ◽  
Healthy Male ◽  
Autoimmune Thyroid

COVID-19 is implicated in triggering autoimmune, dermatologic, and thyroid diseases. We present a first known case of development of Graves’ disease and psoriasis vulgaris in a previously healthy male teenager without any family history, diagnosed after COVID-19 infection. Evaluation of “long COVID syndrome” should include thorough history and thyroid evaluation.

scholarly journals Co-existent ocular myasthenia gravis and Graves’ disease in a 5 year old

2021 ◽  
Vol 2 (4) ◽  
Author(s):  
Olivia Watson ◽  
Michelle Jack ◽  
Helen Young
Keyword(s):  
Myasthenia Gravis ◽  
Thyroid Disease ◽  
Autoimmune Thyroid Disease ◽  
Clinical Presentation ◽  
Graves Disease ◽  
Autoimmune Thyroid ◽  
Ocular Myasthenia ◽  
Ocular Myasthenia Gravis ◽  
The Relationship ◽  
Symptom Recurrence

Myasthenia gravis and Graves’ disease are known to co-exist in adults, yet there have only been a small number of paediatric cases reported. We report a 5 year old female who was diagnosed with ocular myasthenia gravis after presenting with unilateral ptosis and subsequently found also to have Graves’ disease. She was treated successfully with pyridostigmine, corticosteroids and carbimazole without symptom recurrence or progression to generalised myasthenia gravis. The aetiology of the coexistence is not fully understood, nor is the relationship between the two disorders’ presentation and treatment. We discuss the variation in clinical presentation of myasthenia gravis between populations and when associated with autoimmune thyroid disease, potential HLA-related genetic susceptibility and the varying approaches to treatment of the co-existent disorders.

scholarly journals Familial dysalbuminemic hyperthyroxinemia confounding management of coexistent autoimmune thyroid disease

2020 ◽  
Vol 2020 ◽  
Author(s):  
Serena Khoo ◽  
Greta Lyons ◽  
Andrew Solomon ◽  
Susan Oddy ◽  
David Halsall ◽  
...  
Keyword(s):  
Thyroid Hormone ◽  
Thyroid Disease ◽  
Autoimmune Thyroid Disease ◽  
Graves Disease ◽  
Thyroid Function Tests ◽  
Thyroid Status ◽  
Free T4 ◽  
Autoimmune Thyroid ◽  
Analytical Interference ◽  
Tsh Levels

Summary Familial dysalbuminemic hyperthyroxinemia (FDH) is a cause of discordant thyroid function tests (TFTs), due to interference in free T4 assays, caused by the mutant albumin. The coexistence of thyroid disease and FDH can further complicate diagnosis and potentially result in inappropriate management. We describe a case of both Hashimoto’s thyroiditis and Graves’ disease occurring on a background of FDH. A 42-year-old lady with longstanding autoimmune hypothyroidism was treated with thyroxine but in varying dosage, because TFTs, showing high Free T4 (FT4) and normal TSH levels, were discordant. Discontinuation of thyroxine led to marked TSH rise but with normal FT4 levels. She then developed Graves’ disease and thyroid ophthalmopathy, with markedly elevated FT4 (62.7 pmol/L), suppressed TSH (<0.03 mU/L) and positive anti-TSH receptor antibody levels. However, propylthiouracil treatment even in low dosage (100 mg daily) resulted in profound hypothyroidism (TSH: 138 mU/L; FT4: 4.8 pmol/L), prompting its discontinuation and recommencement of thyroxine. The presence of discordant thyroid hormone measurements from two different methods suggested analytical interference. Elevated circulating total T4 (TT4), (227 nmol/L; NR: 69–141) but normal thyroxine binding globulin (TBG) (19.2 µg/mL; NR: 14.0–31.0) levels, together with increased binding of patient’s serum to radiolabelled T4, suggested FDH, and ALB sequencing confirmed a causal albumin variant (R218H). This case highlights difficulty ascertaining true thyroid status in patients with autoimmune thyroid disease and coexisting FDH. Early recognition of FDH as a cause for discordant TFTs may improve patient management. Learning points: The typical biochemical features of familial dysalbuminemic hyperthyroxinemia (FDH) are (genuinely) raised total and (spuriously) raised free T4 concentrations due to enhanced binding of the mutant albumin to thyroid hormones, with normal TBG and TSH concentrations. Given the high prevalence of autoimmune thyroid disease, it is not surprising that assay interference from coexisting FDH may lead to discordant thyroid function tests confounding diagnosis and resulting in inappropriate therapy. Discrepant thyroid hormone measurements using two different immunoassay methods should alert to the possibility of laboratory analytical interference. The diagnosis of FDH is suspected if there is a similar abnormal familial pattern of TFTs and increased binding of radiolabelled 125I-T4 to the patient’s serum, and can be confirmed by ALB gene sequencing. When autoimmune thyroid disease coexists with FDH, TSH levels are the most reliable biochemical marker of thyroid status. Measurement of FT4 using equilibrium dialysis or ultrafiltration are more reliable but less readily available.

scholarly journals Associations between NLRC4 Gene Polymorphisms and Autoimmune Thyroid Disease

2020 ◽  
Vol 2020 ◽  
pp. 1-9
Author(s):  
Xuerong Liu ◽  
Xiaogang Bai ◽  
Jing Zhao ◽  
Chaoqun Gao ◽  
Peng Du ◽  
...  
Keyword(s):  
Hashimoto’S Thyroiditis ◽  
Hashimoto's Thyroiditis ◽  
Genotype Distribution ◽  
Healthy Controls ◽  
Dominant Model ◽  
Autoimmune Thyroid Diseases ◽  
Age And Gender ◽  
Autoimmune Thyroid ◽  
And Gender ◽  
Allele Model

Background. Many studies have shown that NLRC4 inflammasome polymorphisms are associated with a variety of autoimmune diseases, but the associations between NLRC4 polymorphisms and autoimmune thyroid diseases (AITDs) are unclear. Our research was aimed at identifying the correlations between NLRC4 polymorphisms and AITDs. Methods. Hi-SNP high-throughput genotyping technology was used for detecting four single-nucleotide polymorphisms (SNPs) of NLRC4 in 1005 AITDs patients (including 629 Graves’ disease and 376 Hashimoto’s thyroiditis) and 781 healthy controls. Results. Compared with healthy controls, the allele frequencies and genotype distribution of rs385076 were statistically related to AITDs (P=0.016 and P=0.048, respectively) and Hashimoto’s thyroiditis (P=0.022 and P=0.046, respectively). Before adjusting for age and gender, rs385076 and AITDs had a significant association in three models of allele model, dominant model, and homozygous model. After adjusting for age and gender, in the above three models, there is still a clear relationship between them. Before adjusting for age and gender, there were prominent discrepancy between rs385076 and Hashimoto’s thyroiditis in the allele model (OR=0.81, 95% CI 0.67-0.97; P=0.021) and the dominant model (OR=0.73, 95% CI 0.57-0.94; P=0.014), after adjusting for age and gender, rs385076 and Hashimoto’s thyroiditis were significantly related to allele model, dominant model, and homozygous model. However, rs455060, rs212704, and rs675712 were not related to AITDs in our study. Conclusion. NLRC4 rs385076 was found to have a significant association with Hashimoto’s thyroiditis for the first time. It laid a foundation for the disclosure of the pathogenesis of AITDs, and provided a possible treatment prospect for HT.

Sign in / Sign up

Export Citation Format

Share Document